Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.81 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL6 | P05231 | 1/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.56 |
| ▸ | GLUL | P15104 | 1/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone Acetate SCHEMBL16144480 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL21546231 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL145794 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL11055358 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL3437554 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL1657958 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL145795 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL9802690 | 0.99 | PGR (0.98) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL2272744 | 0.99 | PGR (0.98) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL8987980 | 0.99 | PGR (0.98) | PGRCYP3A4ARF2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14430 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12589102-B2 | Injectable sustained-release formulations for treatment of joint pain and inflammation | FORDOZ PHARMA CORP. (US) | 2026-03-31 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3820479-B1 | METHODS TO REDUCE COMPLICATIONS OF INTRA-ARTICULAR STEROID | TAIWAN LIPOSOME CO LTD (TW) | 2026-03-11 | — | — | EP | claimed |
| EP-4673549-A1 | COMPOSITIONS AND METHODS FOR IMPROVED ADENOVIRAL- BASED GENE THERAPY UTILIZING CORTICOSTEROID TREATMENT | Pacira Therapeutics, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| EP-3426327-B1 | NEEDLELESS INJECTION DEVICE EQUIPPED WITH AN IMPROVED INJECTION NOZZLE | CROSSJECT (FR) | 2025-07-09 | — | — | EP | claimed |
| US-12337065-B2 | Compositions for treating viral infections and methods for same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-06-24 | — | — | US | claimed |
| WO-1990003782-A2 | FINELY DIVIDED SOLID CRYSTALLINE POWDERS VIA PRECIPITATION INTO AN ANTI-SOLVENT | THE UPJOHN COMPANY (US) | 1990-04-19 | — | — | WO | claimed |
| EP-0336902-A2 | Antiinflammatory skin moisturizing composition and method of preparing same | WARNER-LAMBERT COMPANY (US) | 1989-10-11 | — | — | EP | claimed |
| WO-1989001482-A1 | IMPROVED 9alpha-DEHALOGENATION PROCESS | THE UPJOHN COMPANY (US) | 1989-02-23 | — | — | WO | claimed |
| CN-88102018-A | 1-Phenyl-3-naphthyloxypropylamine | — | 1988-10-26 | — | — | CN | claimed |
| WO-1988003799-A1 | PHARMACEUTICAL VEHICLES FOR REDUCING TRANSDERMAL FLUX | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| EP-0004466-B1 | DEMETHYL MAYTANSINOIDS AND METHODS FOR PRODUCING THEM | Takeda Chemical Industries, Ltd. (JP) | 1982-01-27 | — | — | EP | claimed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | claimed |
| US-4083974-A | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | claimed |
| US-4012508-A | Topical composition and method | BURTON VERNA M | 1977-03-15 | — | — | US | claimed |
| US-3959451-A | Recovery of sulfur dioxide from gas mixtures | ASARCO INCORPORATED (US) | 1976-05-25 | — | — | US | claimed |